Clinical trials: Small Cell Cancer Of The Lung
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of programmed cell death 1 (PD-1) inhibitors in advanced lung cancer, such as pembrolizumab…
- Trial name
- NCT04856176
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Advanced/Metastatic Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III…
- Trial name
- NCT00723957
- Testing
- Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6)
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 260 people
- Sponsor
- R-Pharm
Small-cell Lung Cancer
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study.
- Trial name
- SUCCEED (NCT06486428)
- Where
- 52 sites in United States
- Volunteers
- 22 people
- Sponsor
- Addario Lung Cancer Medical Institute
NSCLC, Non-small-cell Lung Carcinoma
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
Durvalumab was approved in the Russian Federation for use after both concurrent and subsequent CRT until disease progression. Currently, there is no real-world data regarding the safety and real world effectiveness of durvalumab…
- Trial name
- NIS durvalumab (NCT05456867)
- Where
- 22 sites in Russia
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring
This study will be performed on grade IIIb and grade IV Non Small Cell Lung Cancer (NSCLC) chemotherapy naive patients with good performance status.
- Trial name
- CEPAC-TDM (NCT01326767)
- Testing
- Paclitaxel dosing according to SmPC, Individualized pharmacokinetically driven paclitaxel dosing
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 366 people
- Sponsor
- Central European Society for Anticancer Drug Research
Non-Small Cell Lung Cancer, EGFR
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer
This study is designed to explore whether resecting the primary lung cancer, followed by osimertinib, can improve outcomes for patients with advanced non-small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations (exon…
- Trial name
- SURGAN-TKI (NCT07177092)
- Testing
- Surgery, Osimertinib
- Volunteers
- 118 people
- Sponsor
- Jianxing He
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Whole-Brain Radiotherapy
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
This study is a multicenter, randomized, prospective Phase III study to evaluate the efficacy and safety of anlotinib plus whole-brain radiotherapy (WBRT) compared with WBRT alone in small cell lung cancer (SCLC) patients with…
- Trial name
- NCT07443397
- Testing
- Anlotinib, Whole-brain Radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
S9925: Collecting and Storing Samples From Patients With Lung Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and sputum from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00920010
- Testing
- biologic sample preservation procedure
- Where
- 431 sites in United States
- Volunteers
- 2,264 people
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer
[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.
[18F]F-AraG is a promising tracer to image activated T-cells with positron emission tomography (PET). The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of this novel tracer by performing a full…
- Trial name
- ATTAIN (NCT05157659)
- Testing
- [18F]F-AraG PET-scan
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Amsterdam UMC, location VUmc
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Cutaneous Melanoma, Pleural Mesothelioma
A Study of SGN-CD228A in Advanced Solid Tumors
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer
- Trial name
- NCT04042480
- Testing
- SGN-CD228A
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 88 people
- Sponsor
- Seagen Inc.
Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II trial to study the effectiveness of gefitinib in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00029003
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Non-Squamous Non-Small Cell Lung Cancer
PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line…
- Trial name
- NCT01659970
- Where
- 110 sites in France
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?
Not significantly increased survival in T/T
- Trial name
- NCT02740894
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Lung Cancer
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004151
- Testing
- acridine carboxamide
- Where
- 8 sites in Austria, Denmark and 4 more
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Extensive-Stage Small-Cell Lung Cancer
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
This is an open-label, randomised, multicenter, Phase II study. This study is planned to enroll 90 eligible patients to receive durvalumab combined with up to 4 cycles of etoposide and platinum-based chemotherapy (EP).
- Trial name
- NCT04985851
- Testing
- durvalumab + anlotinib, Durvalumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Chest Hospital